Skip to main content
Canada’s most-awarded newsroom for a reason
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
Canada’s most-awarded newsroom for a reason
$1.99
per week
for 24 weeks
Start Today
// //
Subscribe from $1.99/WK
Register
AdChoices

Biosyent Inc TSX Venture: RX-X

Today's Change
Volume
Real-Time Last Update TSX Venture Last Sale
Alerts Watchlist Portfolio

Today's Trading

Day Low 6.990
Day High 7.000
Open:6.990
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Latest
number cruncher
15 stocks beyond the index that offer growth at a reasonable price
Subscriber content
inside the market
Thursday’s analyst upgrades and downgrades: Rating changes for RBC, National Bank
Subscriber content
inside the market
Thursday’s analyst upgrades and downgrades
Subscriber content
inside the market
Market movers: Stocks that saw action on Monday - and why
Subscriber content
inside the market
Monday’s analyst upgrades and downgrades
Subscriber content
inside the market
Monday’s small-cap stocks to watch
Subscriber content
Description
Biosyent Inc is a specialty pharmaceutical company engaged in developing pharmaceutical and healthcare products. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview. The company through its subsidiaries sources acquires or in-licenses pharmaceutical products and markets the products. Geographically all the activities are functioned through the region of Canada.

Fundamentals

Market Capitalization, $K
Shares Outstanding, K
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

View Earnings

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Hold
View Estimates zacks

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

Download Premium PDF Refinitiv. Trademark. Data is Just the Beginning.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Download Premium PDF StockCalc

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Download Free PDF ValueEngine logo

Latest Press Releases

More Stories
BioSyent Releases Q2 and H1 2021 Financial Results
- GlobeNewswire - Wed Aug 25, 7:00AM CDT
GlobeNewswire - CMTX
Wed Aug 25, 7:00AM CDT
BioSyent Inc. ("BioSyent", TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2021. Key highlights include:
BioSyent Schedules Q2 and H1 2021 Earnings Release for August 25, 2021
- GlobeNewswire - Tue Aug 17, 7:00AM CDT
GlobeNewswire - CMTX
Tue Aug 17, 7:00AM CDT
BioSyent Inc. ("BioSyent", "the Company", TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30, 2021 on Wednesday, August 25, 2021 at 8:00am ET. A presentation on the Company's second quarter and first half 2021 results by Rene Goehrum, BioSyent President and CEO, will also be available on the Company's website on the date of release.
BioSyent Signs Exclusive Technology Agreement
- GlobeNewswire - Tue Jul 13, 7:00AM CDT
GlobeNewswire - CMTX
Tue Jul 13, 7:00AM CDT
BioSyent Inc. ("BioSyent", TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an agreement to license a unique technology application to support better treatment outcomes for patients with iron deficiencies in Canada and BioSyent's international markets.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 6.950 +0.58% increase
on 09/23/21
Period Open:7.500
Price movement based on the high, low and last over the given period.
7.500 -6.80% decrease
on 09/16/21
 -0.510 (-6.80%) decrease
since 09/15/21
3-Month 6.950 +0.58% increase
on 09/23/21
Period Open:7.660
Price movement based on the high, low and last over the given period.
8.300 -15.78% decrease
on 08/18/21
 -0.670 (-8.75%) decrease
since 07/15/21
52-Week 6.590 +6.07% increase
on 11/09/20
Period Open:7.050
Price movement based on the high, low and last over the given period.
9.590 -27.11% decrease
on 06/24/21
 -0.060 (-0.85%) decrease
since 10/15/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies